I-MAK’s Distorted View of the U.S. Patent System

In an opinion piece published at CNBC.com, Tahir Amin — co-founder of I-MAK — blames the U.S. patent system for our country’s “high drug prices.” The author commits many of the same errors we see regularly from critics of the biotech industry.
For example, he ignores the fact that the trend on prescription drug costs is actually heading in the right direction. Not surprisingly, he also neglects to mention that insurance companies have continued to shift more prescri